Multiple Sclerosis

	11/26/2009	TopAbstracts in Multiple Sclerosis 11/26/2009 - (DGNews)
	11/26/2009	Women With MS No More Likely to Have Pregnancy Complications Than General Population - (DGNews)
	11/16/2009	MS More Aggressive in Children but Slower to Cause Disability Than in Adults - (DGNews)
	11/12/2009	TopAbstracts in Multiple Sclerosis 11/12/2009 - (DGNews)
	10/29/2009	TopAbstracts in Multiple Sclerosis 10/29/2009 - (DGNews)
	10/18/2009	Experimental Drug Reduces Pseudobulbar Affect in Patients With MS, ALS: Presented at ANA - (DGDispatch)
	10/15/2009	TopAbstracts in Multiple Sclerosis 10/15/2009 - (DGNews)
	10/06/2009	Glatiramer Acetate Treatment Reduces Risk of Early MS Progressing to Clinically Definite Disease - (DGNews)
	10/01/2009	TopAbstracts in Multiple Sclerosis 10/01/2009 - (DGNews)
	09/23/2009	Fampridine Sustained-Release Tablets Beneficial as Long-Term Therapy for Patients With MS: Presented at EFNS - (DGDispatch)
	09/23/2009	Asymptomatic reactivation of JC virus in patients treated with natalizumab (N Engl J Med)
	09/23/2009	Progressive multifocal leukoencephalopathy after natalizumab monotherapy (N Engl J Med)
	09/23/2009	Treatment of progressive multifocal leukoencephalopathy associated with natalizumab (N Engl J Med)
	09/22/2009	FDA Continues to Receive Reports of PML in Patients Receiving Natalizumab - (DGNews)
	09/17/2009	TopAbstracts in Multiple Sclerosis 09/17/2009 - (DGNews)
	09/17/2009	Dirucotide Shows No Significant Treatment Effects Compared With Placebo in Secondary-Progressive MS: Presented at ECTRIMS - (DGDispatch)
	09/17/2009	Natalizumab's Efficacy Confirmed in Postmarket Clinical Practice: Presented at ECTRIMS - (DGDispatch)
	09/16/2009	Atorvastatin Decreases New Brain MRI T2 Lesion Activity in Patients With Clinically Isolated Syndrome: Presented at ECTRIMS - (DGDispatch)
	09/16/2009	Cladribine Safe and Tolerable, Improves Outcomes in Patients With Relapsing-Remitting MS: Presented at ECTRIMS - (DGDispatch)
	09/14/2009	Sustained Release Fampridine Provides Improvement in Walking Speed for Subset of Patients With MS Over Long Term: Presented at ECTRIMS - (DGDispatch)
	09/14/2009	Alemtuzumab Treatment Benefits Continue Into Fourth Year of Follow-Up for Patients With Relapsing-Remitting MS: Presented at ECTRIMS - (DGDispatch)
	09/14/2009	Subcutaneous IFN Beta-1a Provides Significant Short-Term Efficacy, Tolerability in Relapsing-Remitting MS: Presented at ECTRIMS - (DGDispatch)
	09/14/2009	Adding Teriflunomide to IFN-Beta Treatment Improves Disease Control in Patients With Relapsing MS: Presented at ECTRIMS - (DGDispatch)
	09/14/2009	Nabiximols Effective and Well Tolerated for Patients Suffering From Refractory Spasticity in MS: Presented at ECTRIMS - (DGDispatch)
	09/14/2009	Glatiramer Acetate and IFN Beta Both Improve Cognitive Function and Depression in Patients With Relapsing-Remitting MS: Presented at ECTRIMS - (DGDispatch)
	09/14/2009	Temsirolimus Reduces Rate of Brain Atrophy in Patients With Relapsing-Remitting MS: Presented at ECTRIMS - (DGDispatch)
	09/14/2009	Oral Fingolimod Shows Superior Clinical Efficacy Compared With Interferon Beta-1a in Relapsing-Remitting MS: Presented at ECTRIMS - (DGDispatch)
	09/14/2009	Methylprednisolone Plus IFN Beta-1a Shows Promise in MS Treatment: Presented at ECTRIMS - (DGDispatch)
	09/12/2009	Glatiramer Acetate Reduces Disease Severity for Patients Treated Early for Mild Relapsing-Remitting MS: Presented at ECTRIMS - (DGDispatch)
	09/12/2009	Alemtuzumab Improves Disability in Patients With Relapsing-Remitting MS Independent of Relapse History: Presented at ECTRIMS - (DGDispatch)